10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Clinical Trial ID: NCT00568997

Description

This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

Registry study to examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.


Criteria

Inclusion Criteria: - males and females - greater than or equal to 2 years and less than or equal to 17 years at enrollment - diagnosis of atopic dermatitis (confirmed by treating physician) - applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks Exclusion Criteria: - past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease - past or present use of oral immunosuppressive therapy

  • Start Date

    2005-06-27

  • Last Updated

    2017-12-08

  • Sponsor

    Clinical Research Computing Unit (University of Pennsylvania)

  • Condition Name

    Atopic Dermatitis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.